Hiệu quả điều trị trúng đích trên bệnh nhân ung thư phổi không tế bào nhỏ giai đoạn muộn có và không có đột biến gen egfr

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Đình Hồ Đỗ, Minh Hà Nguyễn, Thành Văn Tạ, Huy Thịnh Trần, Vân Khánh Trần

Ngôn ngữ: vie

Ký hiệu phân loại: 616 Diseases

Thông tin xuất bản: Nghiên cứu y học, 2014

Mô tả vật lý: 45457

Bộ sưu tập: Metadata

ID: 564797

Thêm vào giỏ

Tóm tắt
Chủ đề

Targeted therapy is an effective method for treatment of non-small cell lung cancer (NSCLC). However, the response was demonstrated only in EGFR-mutated NSCLC patients. Objectives of the study were to assess the overall response rate (ORR) for the targeted therapy in EGFR - mutated and non EGFR - mutated advanced NSCLC patients
Comparing the progressive-free survival (PFS) and the overall survival (OS) after the targeted therapy of these two groups of patients. 80 gefitinib or erlotinib - treated stage IIIB/IV NSCLC patients were selected for this study
Identify mutation by sequencing and Scorpions ARMS techniques
Observe the response of the targeted treatment after 3 and 6 months
compare the PFS and OS of the subgroups. no complete response was observed after 3 and 6 months of targeted treatment. ORR tends to decrease in non EGFR - mutated group compared with EGFR - mutated group. There was a statistically significant improvement in both PFS and OS of EGFR - mutated group. Gefitinib or erlotinib can prolong the survival of the advanced NSCLC patients harboring EGFR mutations.

Tạo bộ sưu tập với mã QR